Command Palette
Search for a command to run...
Nephrocare Health Services
NSE: NEPHROPLUSBSE: 544647HEALTHCAREHEALTHCARE SERVICES
Market Cap
--
P/E Ratio
0.00
P/B Ratio
0.00
ROE
0.00%
ROA
0.00%
Debt/Equity
0.00
Book Value
₹0.0
EPS
₹0.0
About Nephrocare Health Services
Nephrocare Health Services was incorporated on December 18, 2009. The company provides dialysis treatment across India and Asia, offering services like haemodialysis, home dialysis, and mobile dialysis. It operates 490 clinics, including international ones, and serves over 29,000 patients annually
Nephrocare Health Services Limited was incorporated as "Nephrocare Health Services Private Limited", a private limited company at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh on December 18, 2009. Company was converted into a public limited company and the name was changed to "Nephrocare Health Services Limited" with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. Company offer comprehensive dialysis care through a network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. The Company began journey in 2010 with the launch of its first dialysis clinic in Hyderabad. It launched first Public Private Partnership (PPP) clinic in Sananth Nagar, Hyderabad in 2012; acquired 100% stake in DaVita Care (India) Private Limited, the Indian arm of DaVita Care Pte Ltd. in 2018; launched operations in Philippines by acquiring Royal Care Dialysis Center, Inc in 2020. The Company acquired 6 clinics dialysis network with 35000 annual tretaments in 2023 . Further, it has acquired a chain of 7 clinics dialysis network such as AIZ Hemodialysis Center Inc., Bioregen Hemo Center Inc., Carmona Dialysis System Inc., Infini Care Health Systems Inc., and Kolff Dialysis Inc. in FY25. Company is planning to raise funds of fresh issue of Rs 353.4 Cr equity shares having the face value of Rs 2/- each, by issuing 12,792,056 equity shares through offer for sale.
Price Action • NEPHROPLUS
Financial Statements
Consolidated & Standalone Reports
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 |
|---|---|---|---|---|
Total Revenue | 0 | 559.23 | 444.03 | 391.2 |
Operating Expenses | 0 | 448.71 | 384.27 | 348.14 |
Operating Profit | 0 | 94.88 | 51.96 | 37.97 |
Operating Margin (%) | - | 16.97 | 11.7 | 9.71 |
Total Expenses | - | 513.87 | 443.82 | 404.08 |
EBITDA | - | 110.51 | 59.77 | 43.06 |
EBITDA Margin (%) | - | 19.76 | 13.46 | 11.01 |
Interest Expenses | 0 | 14.3 | 16.82 | 15.03 |
Depreciation | 0 | 50.86 | 42.73 | 40.91 |
Profit Before Tax (PBT) | 0 | 45.36 | 0.22 | -12.88 |
Tax Expenses | 0 | 11.12 | -3.66 | 2.59 |
PAT Before Extraordinary Items | - | 34.24 | 3.88 | -15.46 |
Net Profit | 0 | 34.24 | 3.88 | -15.46 |
Net Profit Margin (%) | - | 6.29 | 0.88 | -4 |
EPS (Adjusted) | - | 3.41 | 0.39 | -1.54 |
Valuation & Key Ratios
Performance Metrics
| Metric | TTM | Mar '25 | Mar '24 | Mar '23 |
|---|---|---|---|---|
Book Value Per Share | - | 3,050.1 | 2,291.71 | 2,260.06 |
Return on Assets (ROA) % | - | 4.52 | 0.58 | -2.39 |
Return on Equity (ROE) % | - | 6.35 | 0.96 | -3.93 |
Return on Capital Employed (ROCE) % | - | 9.91 | 3.55 | 0.43 |
Profitability Ratios | - | - | - | - |
Liquidity Ratios | - | - | - | - |
Valuation Ratios | - | - | - | - |
Debt to Equity Ratio | 0 | 0.23 | 0.45 | 0.5 |
Featured Insight
No recent news available